Clinical Trial Update: Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating rapid plasma genotyping to initiate erlotinib early in EGFR-mutant non-small cell lung cancer was terminated; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Epidermal Growth Factor Receptor, Non-Small Cell Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2019-11-22